FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225515641> ?p ?o ?g. }

• W4225515641 endingPage "1759720X2210848" @default.
• W4225515641 startingPage "1759720X2210848" @default.
• W4225515641 abstract "Achondroplasia is the most common short-limbed skeletal dysplasia resulting from gain-of-function pathogenic variants in fibroblast growth factor receptor 3 (FGFR3) gene, a negative regulator of endochondral bone formation. Most treatment options are symptomatic, targeting medical complications. Infigratinib is an orally bioavailable, FGFR1-3 selective tyrosine kinase inhibitor being investigated as a direct therapeutic strategy to counteract FGFR3 overactivity in achondroplasia.The main objective of PROPEL is to collect baseline data of children with achondroplasia being considered for future enrollment in interventional studies sponsored by QED Therapeutics. The objectives of PROPEL 2 are to obtain preliminary evidence of safety and efficacy of oral infigratinib in children with achondroplasia, to identify the infigratinib dose to be explored in future studies, and to characterize the pharmacokinetic (PK) profile of infigratinib and major metabolites.PROPEL (NCT04035811) is a prospective, noninterventional clinical study designed to characterize the natural history and collect baseline data of children with achondroplasia over 6-24 months. PROPEL 2 (NCT04265651), a prospective, phase II, open-label study of infigratinib in children with achondroplasia, consists of a dose-escalation, dose-finding, and dose-expansion phase to confirm the selected dose, and a PK substudy.Children aged 3-11 years with achondroplasia who completed ⩾6 months in PROPEL are eligible for PROPEL 2. Primary endpoints include treatment-emergent adverse events and change from baseline in annualized height velocity. Four cohorts at ascending dose levels are planned for dose escalation. The selected dose will be confirmed in the dose-expansion phase.PROPEL and PROPEL 2 are being conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, principles of the Declaration of Helsinki, and relevant human clinical research and data privacy regulations. Protocols have been approved by local health authorities, ethics committees, and institutions as applicable. Parents/legally authorized representatives are required to provide signed informed consent; signed informed assent by the child is also required, where applicable.PROPEL and PROPEL 2 will provide preliminary evidence of the safety and efficacy of infigratinib as precision treatment of children with achondroplasia and will inform the design of future studies of FGFR-targeted agents in achondroplasia.ClinicalTrials.gov: NCT04035811; NCT04265651." @default.
• W4225515641 created "2022-05-05" @default.
• W4225515641 creator A5000857707 @default.
• W4225515641 creator A5000891412 @default.
• W4225515641 creator A5001570533 @default.
• W4225515641 creator A5001767521 @default.
• W4225515641 creator A5004969502 @default.
• W4225515641 creator A5006532808 @default.
• W4225515641 creator A5006745801 @default.
• W4225515641 creator A5008365701 @default.
• W4225515641 creator A5025914068 @default.
• W4225515641 creator A5028724151 @default.
• W4225515641 creator A5031316607 @default.
• W4225515641 creator A5033079105 @default.
• W4225515641 creator A5034336613 @default.
• W4225515641 creator A5037914599 @default.
• W4225515641 creator A5040237112 @default.
• W4225515641 creator A5042446335 @default.
• W4225515641 creator A5042951745 @default.
• W4225515641 creator A5049896329 @default.
• W4225515641 creator A5049904372 @default.
• W4225515641 creator A5061306814 @default.
• W4225515641 creator A5069130924 @default.
• W4225515641 creator A5072762008 @default.
• W4225515641 creator A5077589167 @default.
• W4225515641 creator A5078684328 @default.
• W4225515641 creator A5084662708 @default.
• W4225515641 creator A5090295108 @default.
• W4225515641 date "2022-01-01" @default.
• W4225515641 modified "2023-10-17" @default.
• W4225515641 title "Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies" @default.
• W4225515641 cites W1597997618 @default.
• W4225515641 cites W1966000815 @default.
• W4225515641 cites W1967485093 @default.
• W4225515641 cites W1988289042 @default.
• W4225515641 cites W1989347592 @default.
• W4225515641 cites W2012322174 @default.
• W4225515641 cites W2063656824 @default.
• W4225515641 cites W2073755550 @default.
• W4225515641 cites W2162343930 @default.
• W4225515641 cites W2319017331 @default.
• W4225515641 cites W2589743791 @default.
• W4225515641 cites W2769909737 @default.
• W4225515641 cites W2805915033 @default.
• W4225515641 cites W2947905904 @default.
• W4225515641 cites W2950774550 @default.
• W4225515641 cites W2993284257 @default.
• W4225515641 cites W3010292777 @default.
• W4225515641 cites W3022256972 @default.
• W4225515641 cites W3081737776 @default.
• W4225515641 cites W3124300104 @default.
• W4225515641 cites W3128786825 @default.
• W4225515641 cites W3216831752 @default.
• W4225515641 cites W4211105381 @default.
• W4225515641 doi "https://doi.org/10.1177/1759720x221084848" @default.
• W4225515641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35342457" @default.
• W4225515641 hasPublicationYear "2022" @default.
• W4225515641 type Work @default.
• W4225515641 citedByCount "11" @default.
• W4225515641 countsByYear W42255156412022 @default.
• W4225515641 countsByYear W42255156412023 @default.
• W4225515641 crossrefType "journal-article" @default.
• W4225515641 hasAuthorship W4225515641A5000857707 @default.
• W4225515641 hasAuthorship W4225515641A5000891412 @default.
• W4225515641 hasAuthorship W4225515641A5001570533 @default.
• W4225515641 hasAuthorship W4225515641A5001767521 @default.
• W4225515641 hasAuthorship W4225515641A5004969502 @default.
• W4225515641 hasAuthorship W4225515641A5006532808 @default.
• W4225515641 hasAuthorship W4225515641A5006745801 @default.
• W4225515641 hasAuthorship W4225515641A5008365701 @default.
• W4225515641 hasAuthorship W4225515641A5025914068 @default.
• W4225515641 hasAuthorship W4225515641A5028724151 @default.
• W4225515641 hasAuthorship W4225515641A5031316607 @default.
• W4225515641 hasAuthorship W4225515641A5033079105 @default.
• W4225515641 hasAuthorship W4225515641A5034336613 @default.
• W4225515641 hasAuthorship W4225515641A5037914599 @default.
• W4225515641 hasAuthorship W4225515641A5040237112 @default.
• W4225515641 hasAuthorship W4225515641A5042446335 @default.
• W4225515641 hasAuthorship W4225515641A5042951745 @default.
• W4225515641 hasAuthorship W4225515641A5049896329 @default.
• W4225515641 hasAuthorship W4225515641A5049904372 @default.
• W4225515641 hasAuthorship W4225515641A5061306814 @default.
• W4225515641 hasAuthorship W4225515641A5069130924 @default.
• W4225515641 hasAuthorship W4225515641A5072762008 @default.
• W4225515641 hasAuthorship W4225515641A5077589167 @default.
• W4225515641 hasAuthorship W4225515641A5078684328 @default.
• W4225515641 hasAuthorship W4225515641A5084662708 @default.
• W4225515641 hasAuthorship W4225515641A5090295108 @default.
• W4225515641 hasBestOaLocation W42255156411 @default.
• W4225515641 hasConcept C126322002 @default.
• W4225515641 hasConcept C187212893 @default.
• W4225515641 hasConcept C197934379 @default.
• W4225515641 hasConcept C2777288759 @default.
• W4225515641 hasConcept C2780472190 @default.
• W4225515641 hasConcept C71924100 @default.
• W4225515641 hasConceptScore W4225515641C126322002 @default.
• W4225515641 hasConceptScore W4225515641C187212893 @default.
• W4225515641 hasConceptScore W4225515641C197934379 @default.

• next